Market Highlights
Facial paralysis is a restriction of the facial movement due to nerve damage. Facial nerve paralysis is characterized by unilateral facial weakness. Some other symptoms include loss of taste, hyperacusis, and decreased salivation and tear secretion.
Asia Pacific is the fastest growing market for facial paralysis whose growth is attributed to the rising population and increasing standard of living. Additionally, the increasing healthcare spending and the improved standard of living are likely to drive the growth of the market. India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and the increasing demand for diagnostic services.
Facial Paralysis market Size was valued at USD 2.3 Billion in 2022. The facial paralysis market industry is projected to grow from USD 2.41 Billion in 2023 to USD 3.507 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.80% during the forecast period (2023 - 2032).
Segmentation
The global facial paralysis market is segmented on the basis of treatment, diagnosis, type, and end-user.
On the basis of type, the market is segmented into, Ramsay Hunt Syndrome, facial erythema, Bell’s Palsy, and Lyme Disease.
On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.
On the basis of treatment, the market is segmented into medications, physical therapy, and surgery.
On the basis of medication, the market is further sub-segmented into corticosteroids and antiviral drugs.
On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.
Regional Analysis
The Americas dominates the global facial paralysis market owing to increasing cardiovascular disorders, which eventually leads to the increasing patient population. Additionally, increasing cardiovascular disorder rate is likely to enhance the growth of facial paralysis in the North American region. According to the American Heart Association, 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, in 2015, around USD 3.2 trillion were spend in healthcare expenditure in the U.S according to the Center for Disease Control and Prevention. Similarly, in 2015, 1.3% of the U.S. adults were diagnosed with inflammation of facial nerves.
Europe accounts for the second largest market due to increasing cardiovascular disorders and increasing infections. Additionally, the increasing government support and improving healthcare infrastructure along with increasing facial inflammations are driving the growth of the facial paralysis market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to lead to the increasing patient population. These factors are likely to drive the growth of the facial paralysis market.
Key Players
Some of the key Facial Paralysis Market players are, Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.
On the other hand, the Middle East and Africa is expected to witness a gentle growth due to limited access to the healthcare industry and affordability issues among the population. In the Middle East, the growth of the market is driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
